ALK and neoplasm: In the IMpower010 trial, the difference in OS between atezolizumab and best supportive care (BSC) was more pronounced in patients without EGFR/ALK mutations and with PD-L1 tumor cells ≥ 50% (5-year OS 89.1% with atezolizumab and 77.5% with BSC [HR 0.42 (0.23–0.78)] [15].